ChronoScale Completes Ekso Bionics Sale, Terminates COO, and Withdraws Series B Preferred Stock
CHRN has more than doubled off its 52-week low of $3.5.
Summary
ChronoScale completed the sale of its Ekso Bionics unit, terminated the subsidiary's COO with a $243,750 severance, and withdrew its Series B Preferred Stock designation. The moves streamline the company around its AI infrastructure business.
Key Events · M&A and Partnerships · CHRN
-
Ekso Bionics Sale Completed
ChronoScale completed the sale of its Ekso Bionics subsidiary on September 30, 2026, allowing the company to focus capital and management resources on its core AI infrastructure business.
-
COO Termination and Severance
Jason C. Jones, COO of Ekso, was terminated effective September 30, 2026, and will receive a $243,750 lump-sum severance payment plus up to nine months of COBRA coverage.
-
Series B Preferred Stock Withdrawn
The company filed a Withdrawal of Designation for 5,852 shares of Series B Convertible Preferred Stock on September 29, 2026, with no shares outstanding at the time of withdrawal.
-
Strategic Focus on AI Infrastructure
The divestiture follows the October 1 announcement of $1 billion in contracted run-rate revenue by Q3 2027, positioning ChronoScale as a pure-play accelerated compute platform.
Analysis · CHRN · Technology
ChronoScale finalized the sale of its Ekso Bionics business unit on September 30, 2026, a divestiture that sharpens its focus on AI infrastructure. The transaction triggered the termination of Ekso COO Jason C. Jones with a $243,750 severance package. Separately, the company withdrew the designation of 5,852 shares of Series B Convertible Preferred Stock, eliminating a potential overhang since no shares were outstanding. These actions follow the October 1 announcement of $1 billion in contracted run-rate revenue by Q3 2027, reinforcing the strategic pivot toward accelerated compute.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.5% of the 1055 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CHRN was trading at $19.21 on NASDAQ in the Technology sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $3.50 to $30.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.